Baiming Xinkang (百明信康)

Baiming Xinkang Biotechnology (百明信康生物技术), also known as Worg Pharma, is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, founded in 2018. The company is focused on developing next-generation allergen-specific immunotherapy (ASIT) and other innovative biologics to address unmet medical needs in allergy and autoimmune diseases. Its proprietary PCFiT platform underpins a pipeline of preclinical and late-stage clinical biologics targeting multiple inhalant allergens, and the company has established strategic partnerships with WuXi Biologics for process development and global IND filing. The management team brings extensive experience from China, the United States, and Europe in drug development, clinical trials, regulatory affairs, and commercialization.